Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections
A collaborative project financed by the EC Framework Programme 7
von Delft A et al., Vaccine. 2018 Jan 4;36(2):313-321 - The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
Hancock G et al., J Int AIDS Soc. 2017 May 19;20(1):21171 - Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.
Ewer et al., Curr Opin Immunol 2016 Jun 7; 41: 47-54 - Viral vectors as vaccine platforms: from immunology to impact.
von Delft A et al., Gut 2015 Jun; 0:1–12 – The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.
Swadling L et al., Sci Transl Med. 2014 Nov 5;6(261):261ra153 – A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
Capone S et al., Mol Ther. 2014 May;22(5):1039-47 – Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates